CRISPR Technologies: from Laboratories to Industry
Product News Nov 07, 2018
Recent advances in genome engineering are starting a revolution in biological and translational applications. CRISPR-Cas9 and its variants enable diverse manipulations of genome function. This genome editing principle spans almost every industry that involves biological systems including: biotech, agritech, therapeutics and diagnostics.
In this context, the market research and strategy consulting company, Yole Développement (Yole) has recently released its first report in the field of Biotechnologies Entitled “CRISPR Technology & Market Overview: from Lab to Industry”, The report illustrates how the US$546 million CRISPR market in 2017 will grow at a rate of 44% year-over-year, reaching US$5 billion by 2023. It brings an overview of the key drivers resulting in high adoption of the technology but also the key challenges impeding the growth of this market. Analysts at Yole Développement identified a wide range of heavyweight companies and startups who jumped on CRISPR seeing its potential in creating specific changes at specific sites. All of these result in developing several business models based on CRISPR technology by key players. The report analyzes also the strategic market opportunities, future scope and includes an intellectual property landscape analysis of the main patent assignees. IP part was conducted in collaboration with Knowmade, a member of Yole Group of companies.
Key results of the CRISPR report have been presented by Asma Siari, Technology & Market Analyst, Biotechnologies & Molecular Innovations, Medical Technologies for the Life Sciences & Healthcare division at Yole, during the PRECISION CRISPR Congress this week. Presentation is today available on i-micronews.com.
Market growth will be driven by the rising adoption of CRISPR technology, announces Yole’ analysts in CRISPR report towards 4 market segments: biotech, agritech, therapeutic and diagnostic. The main sector is the biotechnology one, they add...
The application of CRISPR technology in the area of biotech is focused on the development of models for drug discovery, while in agritech CRISPR enables the creation of innovation tools. Diagnostics and therapeutics represent a small market contribution to this growth since the technology is in its infancy and requires a number of iterations to optimize its efficacy, safety, and specificity. CRISPR-based gene editing provides the ultimate toolbox for genetic manipulation, allowing the appearance of different products and many new applications that are now being investigated and established.
“The biotech market encompasses a wide range of products which consist of CRISPR-Cas9 kits, providing the required endonucleases and reagents for gene editing,” says Asma Siari from Yole. And she adds: “For the other products, CRISPR is considered as a technology enabler, since it is used as a tool to create genetically modified cells, animal models as well as to provide services.”
The global biotech CRISPR market is anticipated to grow at a 39% CAGR between 2017 and 2023 to reach US$3.9 billion. The major factors boosting the CRISPR technology market in biotech is the great need for optimized CRISPR-CAS9 with reduced off-target effects in addition to the biological research based on the use of engineered cells and animals for preclinical studies. The key players are mainly large biotech companies such as Thermo Fisher, IDT, and Horizon Discovery, who have the largest market shares. There are also an increasing number of startups like Aldevron, Synthego, GenScript, and New England Labs who are trying to get part of the pie.
The dynamism of this industry is also supported by a lot of mergers, acquisitions and investments. Therefore, over than US$ 4.5 billion raised from 2013 to 2018 by biotechnologies and biopharmaceutical companies involved in CRISPR-CAS9 technology. As an example, Synthego has just raised $110 million in a Series C financing round. Agritech, therapeutics and diagnostics are additional applications which still in the development stage but hold promising potential to contribute in the overall growth of the CRISPR market. The agritech industry is producing more food than ever before, but as the world’s population rapidly approaches eight billion, modern food production methods will need a radical transformation, making a key driver for CRISPR adoption. However in Europe regulatory issues are slowing the market’s growth.
“For therapeutic and diagnostic applications, no company has an approved product on the market yet”, comments Dr Marjorie Villien, Technology & Market Analyst at Yole and co-author of the report. “Moreover most of the key players in these markets are small start-ups and technology companies like Casebia Therapeutics, CRISPR Therapeutics, Editas Medicine and Intellia.”
Despite the clinical challenges in therapeutic applications including off- target effects, the efficiencies of delivery methods which depend on the types of target cells and tissues, CRISPR is one of the latest technologies with therapeutic potential that could make disruptive changes not only on the way how basic research are conducted but also on the way how diseases will be treated. The diagnostic field is still at a research stage and lots of developments are needed before a CRISPR-based diagnostic test is available for real-world use. Today there are only a few key players working on diagnostic applications based on CRISPR including Mammoth Biosciences, Caribou Biosciences, and MIT.